60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · IEX Real-Time Price · USD
0.232
-0.009 (-3.73%)
At close: May 2, 2024, 3:59 PM
0.222
-0.010 (-4.48%)
After-hours: May 2, 2024, 7:59 PM EDT
SXTP Revenue
In the year 2023, 60 Degrees Pharmaceuticals had annual revenue of $253.57K, a decrease of -50.40%. Revenue in the quarter ending December 31, 2023 was $371.00K with 42.31% year-over-year growth.
Revenue (ttm)
$253.57K
Revenue Growth
-50.40%
P/S Ratio
10.59
Revenue / Employee
$84,524
Employees
3
Market Cap
2.68M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
Dec 31, 2022 | 511.21K | -4.99M | -90.71% |
Dec 31, 2021 | 5.50M | 3.66M | 197.98% |
Dec 31, 2020 | 1.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSXTP News
- 12 hours ago - 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis - GlobeNewsWire
- 7 weeks ago - 60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer - GlobeNewsWire
- 3 months ago - WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering - PRNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering - GlobeNewsWire
- 3 months ago - WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering - PRNewsWire